一线BTK抑制剂联合方案在原发性中枢神经系统淋巴瘤中与更优缓解和PFS相关
这项回顾性研究纳入131例初诊原发性中枢神经系统淋巴瘤患者,按一线诱导方案分为BTKi为基础组(n=85)和传统方案组(n=46),采用多重插补和IPTW平衡基线特征。BTKi组完全缓解率和客观缓解率更高,无进展生存期更优,但总生存差异未达统计学显著。
要点
- BTKi为基础的一线诱导与更高完全缓解率相关(OR 5.50,95%CI 2.25-13.47)。
- BTKi组无进展生存期优于传统方案(HR 0.57,95%CI 0.32-1.00;P=0.048)。
- 总生存差异未达统计学显著(HR 0.65,95%CI 0.31-1.38;P=0.263)。
核心结论
- 在新诊断PCNSL中,一线整合BTKi与他方案相比与更优PFS和更高缓解率相关。
- 该回顾性比较未能得出BTKi对总生存有确定性获益的结论。
研究设计与样本
- 回顾性研究,纳入131例新诊断PCNSL患者,BTKi为基础组85例、传统方案组46例。
- 采用多重插补(m=50)和逆概率治疗加权(IPTW)平衡基线协变量。
主要发现
- BTKi组完全缓解率更高(OR 5.50,95%CI 2.25-13.47;P<0.001)。
- BTKi组客观缓解率更高(OR 2.59,95%CI 1.05-6.36;P=0.038)。
- BTKi组PFS更优(HR 0.57,95%CI 0.32-1.00;P=0.048)。
- 总生存差异无统计学意义(HR 0.65,95%CI 0.31-1.38;P=0.263)。
临床怎么用
- 对初诊PCNSL可考虑一线诱导方案中整合BTKi以改善缓解深度和PFS。
- 因OS获益不确定,治疗决策需结合患者特征与前瞻性证据综合判断。
局限性
- 回顾性设计存在固有混杂,可能影响OS等结局的解读。
- 样本量有限(131例),BTKi组与传统组样本不均衡(85 vs 46)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-dose methotrexate (HD-MTX)-based immunochemotherapy remains the standard for primary CNS lymphoma (PCNSL), yet relapse rates are high and outcomes suboptimal. While Bruton's tyrosine kinase inhibitors (BTKi) demonstrate efficacy in trials, their comparative benefit against conventional regimens in heterogeneous real-world populations remains undefined. We conducted a retrospective study of 131 newly diagnosed patients stratified by frontline induction therapy (BTKi-based, n=85; conventional, n=46), utilizing multiple imputation (m=50) and inverse probability of treatment weighting (IPTW) to balance baseline covariates. In the primary pooled multiple-imputation IPTW analysis, BTKi-based therapy was associated with improved PFS (HR 0.57, 95% CI 0.32-1.00; P=0.048) and a higher complete response rate (OR 5.50, 95% CI 2.25-13.47; P<0.001). The objective response rate was also higher (OR 2.59, 95% CI 1.05-6.36; P=0.038). The overall survival difference was not statistically significant (HR 0.65, 95% CI 0.31-1.38; P=0.263), which may reflect multifactorial confounding inherent in this retrospective comparison. These findings suggest that integrating BTKi into frontline regimens is associated with a favorable PFS profile and improved response in newly diagnosed PCNSL, while definitive OS conclusions cannot be drawn.
引用
- Wang X, Bai B, Yu S, et al. Frontline Bruton tyrosine kinase inhibitors are associated with improved response and PFS in primary CNS lymphoma. Blood Adv. 2026. PMID: 42913449. doi:10.1182/bloodadvances.2026020093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。